Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -41.18% is in line with its 5-year average of -40.22%, around the middle of its 5-year range (-86.55%–-4.08%).
31.63% above its 12-month average of -60.23%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.20%.
RETURN ON ASSETS (ROA)
-41.18%
RETURN ON ASSETS (ROA) AVG TTM
-60.23%
RETURN ON ASSETS (ROA) AVG 3Y
-53.11%
RETURN ON ASSETS (ROA) AVG 5Y
-40.22%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+31.63%
CURRENT VS 3Y AVG
+22.46%
CURRENT VS 5Y AVG
-2.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.08%
median of 667 covered companies
CURRENT VS SECTOR MEDIAN
-36.90%
vs the sector median at left
Pasithea Therapeutics Corp.
Market Cap
$15.04M
Return on Assets (ROA)
-41.18%
TTM Avg
-60.23%
3Y Avg
-53.11%
5Y Avg
-40.22%
Market Cap
$15.03M
Return on Assets (ROA)
-201.89%
TTM Avg
-113.65%
3Y Avg
-83.24%
5Y Avg
-72.72%
Market Cap
$15.58M
Return on Assets (ROA)
-213.77%
TTM Avg
-110.51%
3Y Avg
-93.41%
5Y Avg
-68.22%
Market Cap
$15.75M
Return on Assets (ROA)
-38.41%
TTM Avg
-84.87%
3Y Avg
-95.12%
5Y Avg
-75.66%
Market Cap
$14.44M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.24M
Return on Assets (ROA)
-15.57%
TTM Avg
-20.73%
3Y Avg
-20.84%
5Y Avg
-41.87%
Market Cap
$16.15M
Return on Assets (ROA)
-154.34%
TTM Avg
-227.23%
3Y Avg
-240.86%
5Y Avg
-184.63%
Market Cap
$14.02M
Return on Assets (ROA)
-32.53%
TTM Avg
-31.07%
3Y Avg
-30.77%
5Y Avg
-29.89%
Market Cap
$16.58M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | $15.04M | -41.18% | -60.23% | -53.11% | -40.22% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.03M | -201.89% | -113.65% | -83.24% | -72.72% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.58M | -213.77% | -110.51% | -93.41% | -68.22% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | -38.41% | -84.87% | -95.12% | -75.66% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.44M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.24M | -15.57% | -20.73% | -20.84% | -41.87% |
| BioCardia, Inc. (BCDA)vs › | $16.15M | -154.34% | -227.23% | -240.86% | -184.63% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.02M | -32.53% | -31.07% | -30.77% | -29.89% |
| Dyadic International, Inc. (DYAI)vs › | $16.58M | -116.60% | -66.28% | -71.56% | -63.10% |
| Passage Bio, Inc. (PASG)vs › | $13.78M | -143.44% | -68.17% | -65.00% | -57.74% |
ROA
-41.2%
ROE
-42.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -33.91% |
| 2024-12-31 | -86.55% |
| 2023-12-31 | -61.12% |
| 2022-12-31 | -30.85% |
| 2021-12-31 | -4.08% |
| 2020-12-31 | -24.79% |
